Kangaroo Biomedical

Cover Block

Metric	Value
Name	Kangaroo Biomedical
Tagline	iPSC-derived cell therapy for IVF improvement and menopause
Headquarters	San Francisco, CA
Founded	2023
Stage	Seed
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Undisclosed

Links

• Website: https://kangaroobiomedical.com
• LinkedIn: https://www.linkedin.com/in/ernesto-lujan-782469b9/

Executive Summary

Kangaroo Biomedical is an early-stage biotechnology company applying an iPSC-derived cell engineering platform to address infertility and menopause [Kangaroo Biomedical, 2026]. Founded in 2023, the company has attracted venture backing from F4 Fund and VU Venture Partners [Crunchbase, 2026] [F4 Fund, 2025]. Its lead candidate, Fertilo, aims to improve outcomes for in vitro fertilization (IVF) and egg freezing by using engineered ovarian support cells [Kangaroo Biomedical, 2026]. The founding team includes CEO Landice Gao and co-founder Dina Radenkovic [Forbes, 2026] [RocketReach, 2026]. Operating on a B2B model targeting fertility clinics, Kangaroo Biomedical is pre-revenue and pre-commercial, with Fertilo not yet approved by the FDA for safety or efficacy [Kangaroo Biomedical, 2026].

Data Accuracy: YELLOW -- Core company claims and investor presence are documented, but key operational and financial details rely on single or unverified sources.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)

How the Company Got Here

Kangaroo Biomedical was founded in 2023 as a biotechnology company focused on women's reproductive health [Kangaroo Biomedical, 2026]. The company is headquartered in San Francisco, California [bizprofile.net, 2026]. Its founding narrative centers on developing a cell engineering platform using induced pluripotent stem cell (iPSC) technology, with an initial product candidate, Fertilo, aimed at improving outcomes for in vitro fertilization (IVF) and egg freezing [Kangaroo Biomedical, 2026]. A key early milestone was securing investment from the F4 Fund [F4 Fund, 2025]. In 2026, the company reported receiving a funding award from the Advanced Research Projects Agency for Health (ARPA-H) Sprint for Women's Health program [Kangaroo Biomedical, 2026]. The same year, its lead candidate, Fertilo, was listed on ClinicalTrials.gov under identifier NCT06858111 [ClinicalTrials.gov, 2026].

Data Accuracy: YELLOW -- Company claims and registry filings are primary; investor backing is corroborated by a single source. Team details remain partially unverified.

Product and Technology

Kangaroo Biomedical’s core asset is a cell engineering platform based on induced pluripotent stem cells (iPSCs). The company’s first application of this technology is Fertilo, a candidate product designed to act as an adjunct to existing in vitro fertilization (IVF) and egg freezing procedures [Kangaroo Biomedical, 2026]. The company states its iPSC-derived technology is showing promise in clinical studies, though it explicitly notes Fertilo has not been approved by the U.S. Food and Drug Administration for safety or efficacy [Kangaroo Biomedical, 2026]. A second research track is indicated by the company’s receipt of an ARPA-H Sprint for Women’s Health funding award, which is directed toward developing a cell therapy for menopause [Kangaroo Biomedical, 2026].

Data Accuracy: YELLOW -- Product claims are sourced from the company website; regulatory status is clearly stated. No independent technical validation or customer deployment data is available.

Where the Demand Sits

The market for interventions in reproductive health is defined by persistent clinical needs, shifting demographics, and a growing willingness to pay for solutions. The global in vitro fertilization (IVF) market was valued at approximately $23 billion in 2023 [Fortune Business Insights, 2023]. The market for menopause management is estimated at over $16 billion globally [Grand View Research, 2023]. The median age of first-time mothers in the United States reached 30 years old as of 2022 [CDC, 2022]. Kangaroo Biomedical's reported ARPA-H Sprint for Women's Health funding award is a direct beneficiary of the White House Initiative on Women's Health Research [The White House, 2024] [Kangaroo Biomedical website, 2026].

Metric	Value
Global IVF Market (2023)	$23B
Menopause Management Market (2023)	$16B

Data Accuracy: YELLOW -- Market sizing figures are from third-party analyst reports for analogous sectors, not the company's specific SAM. Demand driver citations are from public health and business research.

Competitive Landscape

Kangaroo Biomedical enters a reproductive health market where competition is defined by regulatory approval, clinical evidence, and established distribution channels. Incumbents are dominated by large pharmaceutical companies offering hormonal treatments for ovarian stimulation and menopause, such as Ferring Pharmaceuticals and Merck KGaA. A second incumbent layer consists of established medical device and consumable suppliers for IVF labs, like CooperSurgical and Vitrolife. Adjacent substitutes include a growing field of digital health and diagnostic platforms that use AI to select embryos or predict IVF outcomes, such as Alife Health and Future Fertility. Kangaroo Biomedical's claimed edge rests on its proprietary iPSC-derived cell platform. The company's receipt of an ARPA-H Sprint for Women's Health funding award [Kangaroo Biomedical website, 2026] provides non-dilutive capital and a signal of technical merit. The company is exposed to well-funded, later-stage biotechs working on adjacent cell therapies for reproductive aging, such as Gameto [Crunchbase].

Data Accuracy: ORANGE -- Competitive mapping is inferred from the broader market context as no direct competitors are named in sources; analysis of regulatory and channel exposure is based on standard industry dynamics.

Opportunity

If Kangaroo Biomedical's cell engineering platform translates its early-stage promise into a clinically validated product, the company would be positioned to capture a significant portion of the multi-billion dollar global infertility and women's health markets. The headline opportunity is to become the first FDA-approved cell-based therapy to improve IVF outcomes. The company's selection for an ARPA-H Sprint for Women's Health funding award signals that the underlying science has passed an initial technical review [Kangaroo Biomedical website, 2026].

Scenario	What happens	Catalyst	Why it's plausible
Adjuvant Therapy Adoption	Fertilo is approved as an adjunct therapy for IVF cycles in the U.S.	Positive topline results from the ongoing clinical study (NCT06858111) are published [ClinicalTrials.gov, 2026].	The IVF market is highly sensitive to new technologies that improve reported success rates.
Platform Expansion into Menopause	The underlying iPSC platform proves adaptable for menopausal symptom management.	The ARPA-H award leads to a successful proof-of-concept study [Kangaroo Biomedical website, 2026].	The same cellular mechanisms involved in ovarian function are relevant to hormone production.

Data Accuracy: YELLOW -- Core opportunity narrative is based on company claims and a public clinical trial registration; market size and comparable valuation context are drawn from independent industry reports.

Sources

1. [Kangaroo Biomedical, 2026] Kangaroo Biomedical Website | https://kangaroobiomedical.com
2. [F4 Fund, 2025] Kangaroo Biomedical, Biotech & Life Sciences | https://f4.fund/startups/kangaroobiomedical
3. [Crunchbase, 2026] Kangaroo Biomedical - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/kangaroo-biomedical
4. [Forbes, 2026] Forbes Under 30 | https://www.forbes.com/profile/dina-radenkovic/
5. [RocketReach, 2026] Landice Gao Email & Phone Number | https://rocketreach.co/landice-gao-email_71745461
6. [bizprofile.net, 2026] Kangaroo Biomedical, Inc. San Francisco, CA | https://www.bizprofile.net/ca/san-francisco/kangaroo-biomedical-inc
7. [ClinicalTrials.gov, 2026] NCT06858111 | Fertilo In Vitro Research Study and Trial | https://clinicaltrials.gov/study/NCT06858111
8. [Fortune Business Insights, 2023] In Vitro Fertilization Market Size, Share & Industry Analysis | https://www.fortunebusinessinsights.com/in-vitro-fertilization-market-102088
9. [Grand View Research, 2023] Menopause Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/menopause-market-report
10. [CDC, 2022] Births in the United States, 2022 | https://www.cdc.gov/nchs/products/databriefs/db477.htm
11. [Mercer, 2023] Fertility and Family-Forming Benefits Survey | https://www.mercer.com/our-thinking/health/fertility-and-family-forming-benefits-survey.html
12. [McKinsey & Company, 2023] Closing the women’s health gap | https://www.mckinsey.com/mhi/our-insights/closing-the-womens-health-gap-a-1-trillion-dollar-opportunity-to-improve-lives-and-economies
13. [The White House, 2024] White House Initiative on Women’s Health Research | https://www.whitehouse.gov/briefing-room/statements-releases/2024/02/21/fact-sheet-president-biden-issues-executive-order-and-announces-new-actions-to-advance-womens-health-research-and-innovation/